Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AARD | PRESS-RELEASE | bearish | 8/10 | Aardvark Therapeutics announced the FDA placed a full clinical hold on its IND for ARD-101, covering the Phase 3 HERO tr | May 14, 2026 |
| BDRX | 6-K | neutral | 4/10 | Biodexa Pharmaceuticals filed its 6-K on May 14, 2026, announcing its Annual General Meeting (AGM) scheduled for June 17 | May 14, 2026 |
| BHST | 6-K | neutral | 5/10 | BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8% YoY), in line with its $42-$48M annual guidance. Net loss wid | May 14, 2026 |
| FTLF | 8-K | bearish | 6/10 | FitLife Brands reported Q1 2026 revenue of $25.3M (+59% YoY, driven by the Irwin acquisition) but GAAP net income fell t | May 14, 2026 |
| MNPR | PRESS-RELEASE | bullish | 6/10 | Monopar reported Q1 2026 EPS of -$0.46, beating consensus of -$0.90 by 48.9%, driven by lower-than-expected operating ex | May 14, 2026 |
| MNPR | 8-K | neutral | 4/10 | Monopar Therapeutics reported Q1 2026 net loss of $3.9M ($0.46/share), wider than the $2.6M ($0.38/share) loss in Q1 202 | May 14, 2026 |
| BHST | 6-K | bearish | 6/10 | BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8.2% YoY) but net loss widened to $2.6M from $2.3M, with operati | May 14, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK plc filed a Form 6-K reporting routine acquisitions of ordinary shares by multiple PDMRs (including the CFO, Preside | May 14, 2026 |
| GRMLW | 8-K | neutral | 4/10 | Greenland Mines Ltd filed an 8-K furnishing an investor presentation and press release for the CMI Summit 5 conference. | May 14, 2026 |
| IXHL | PRESS-RELEASE | bullish | 6/10 | Incannex Healthcare announced the commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep apnea, a c | May 14, 2026 |
| BHST | 6-K | neutral | 3/10 | BioHarvest Sciences appointed Nedira Salzman-Frenkel as VP of Business Development for its CDMO division. The appointmen | May 14, 2026 |
| APLS | 25-NSE | neutral | 2/10 | Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May | May 14, 2026 |
| SLXN | PRESS-RELEASE | neutral | 4/10 | Silexion Therapeutics reported positive preclinical data showing its siRNA candidate SIL204 increases MHC-I expression i | May 14, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 5/10 | TOMI Environmental Solutions announced a second SteraMist Hybrid System installation at a large East Coast research univ | May 14, 2026 |
| CURX | 8-K | neutral | 3/10 | Curanex Pharmaceuticals provided a Q1 2026 business update highlighting preclinical progress with lead candidate Phyto-N | May 14, 2026 |
| XRTX | 6-K | bearish | 7/10 | XORTX Therapeutics announced a $5 million public offering of 2,659,574 common shares (or pre-funded warrants) at $1.88 p | May 14, 2026 |
| LTRN | 424B5 | bearish | 7/10 | Lantern Pharma is conducting a dilutive public offering of 1,454,175 shares of common stock at $2.06 per share, plus 681 | May 14, 2026 |
| GHRS | 424B5 | bearish | 6/10 | GH Research PLC filed a 424B5 prospectus supplement to register an at-the-market (ATM) equity offering of up to $200 mil | May 14, 2026 |
| CAMP | 8-K | bullish | 6/10 | CAMP4 Therapeutics presented new preclinical data for CMP-002, its lead ASO candidate for SYNGAP1-related disorder, at t | May 14, 2026 |
| CURX | PRESS-RELEASE | neutral | 3/10 | Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its lead candidate Phyto- | May 14, 2026 |
| DWTX | 8-K | bullish | 6/10 | Dogwood Therapeutics reported Q1 2026 net loss of $5.0M ($0.15/share), beating consensus estimates of -$0.20 by 25%. The | May 14, 2026 |
| SNTI | 8-K | bullish | 7/10 | Senti Bio reported Q1 2026 results with net loss of $4.2M ($0.14/share) vs $14.1M ($1.41/share) in Q1 2025, driven by a | May 14, 2026 |
| GILD | 424B5 | neutral | 4/10 | Gilead Sciences filed a preliminary 424B5 prospectus supplement for a multi-tranche senior unsecured note offering with | May 14, 2026 |
| AIM | 8-K | bullish | 6/10 | AIM ImmunoTech posted a Virtual Investor KOL Connect segment featuring Prof. Dr. Casper H.J. van Eijck discussing Amplig | May 14, 2026 |
| SNTI | PRESS-RELEASE | bullish | 7/10 | Senti Bio reported Q1 2026 EPS of -$0.14, beating consensus of -$0.36 by 61%, on minimal revenue of $16K. The beat is dr | May 14, 2026 |
| APLS | 8-K | bullish | 8/10 | Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merge | May 14, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech issued a press release highlighting a KOL segment discussing Ampligen for late-stage pancreatic cancer. T | May 14, 2026 |
| SNTI | PRESS-RELEASE | bullish | 8/10 | Senti Bio announced a successful Type B RMAT meeting with the FDA, finalizing a single-arm registrational trial strategy | May 14, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4 per share in conting | May 14, 2026 |
| GRI | 8-K | neutral | 5/10 | GRI Bio reported Q1 2026 financial results with a net loss of $2.0M (improved from $3.0M in Q1 2025) and cash of $11.0M, | May 14, 2026 |